Fragile X syndrome, a common form of inherited mental retardation, is caused by the loss of the Fragile X mental retardation protein (FMRP). FMRP, which may regulate translation in neurons, not only associates with specific messenger RNAs (mRNAs) and with microRNAs (miRNAs), but also associates with the components of the miRNA pathway, including the Dicer and Argonaute proteins. It has been proposed that FMRP regulates the translation of its mRNA targets through miRNAs. In this chapter, we describe the protocol to identify the mRNAs and miRNAs associated with FMRP in vivo. The same method could also be applied to other RNA-binding proteins interacting with specific mRNAs or miRNAs.
Introduction
Fragile X syndrome, a common form of inherited mental retardation, is caused by the loss of an RNA-binding protein, FMRP (1) . FMRP, along with its autosomal paralogs, the fragile X-related proteins (FXR1P and FXR2P), compose a small family of RNA-binding proteins (the fragile X-related gene family) that share more than 60% amino acid identity and contain two types of RNA-binding motifs: two ribonucleoprotein (RNP) K homology domains and a cluster of arginine and glycine residues (2, 3) . FMRP associates with polyribosomes in an RNA-dependent manner via messenger RNP (mRNP) particles and can suppress translation both in vitro and in vivo (4) (5) (6) (7) . Through use of a nuclear localization signal and a nuclear export signal, FMRP shuttles between the nucleus and cytoplasm (8) . A current working model is that FMRP is involved in synaptic plasticity through regulation of mRNA transport and local protein synthesis at synapses (9) . To test this model, the identification of the mRNAs specifically bound by FMRP and the structure required for FMRP-RNA interaction in mammals has been extensively investigated. Using different approaches, a number of different groups have identified in vivo mRNA cargos associated with FMRP (10, 11) . Using in vitro RNA selection approach, an intramolecular G-quartet RNA was identified as a highaffinity target for the arginine and glycine residue cluster of FMRP, whereas a sequencespecific element within a complex tertiary structure, termed the FMRP kissing complex, was identified as the target of the FMRP second K homology domain (12) (13) (14) .
MiRNAs, a recently discovered class of noncoding RNAs, are believed to control translation of specific target mRNAs by base pairing with complementary sequences in the 3' untranslated region of these messages (15) . The accumulation of recent works from several groups strongly supports the idea that FMRP may regulate the translation of its mRNA via the miRNA pathway (16) (17) (18) . A likely scenario is that once FMRP binds to its specific mRNA ligands, it recruits a RNA-induced silencing complex along with miRNAs and facilitates the recognition between miRNAs and their mRNA ligands. Thus, FMRP might modulate the efficiency of translation of its mRNA targets using miRNAs. This mechanism would allow this activity to be rapid and reversible, as would be needed in protein synthesis-dependent synaptic plasticity. Understanding how FMRP use miRNAs to modulate the translation of its mRNA ligands will help understanding not only of the molecular pathogenesis of fragile X syndrome, but also of miRNA-mediated translational regulation.
To test the hypothesis that translational control involving FMRP is executed in a complex that involves one or more miRNAs interacting with transcripts at specific sites, the identification of mRNAs and miRNAs associated with FMRP will be critical. In this chapter, we describe the immunopurification procedure to characterize the mRNAs and miRNAs in an FMRP-containing mRNP complex. In this method, FMRP-containing mRNP complex is immunoprecipitated with a specific antibody against FMRP. The coimmunoprecipitated RNA is analyzed using different techniques (Fig. 1) . The same methodology could also be applied to other RNA-binding proteins to identify the copurifying RNAs. 
Materials

Immunoprecipitation of FMRP-Containing mRNP Complex
Methods
The methods described here outline the following: During these procedures, it is essential to develop a program of RNase control involving reagent preparation and testing, routine decontamination, and the use of certified RNase-free reagents and equipment, such as microcentrifuge tubes and pipet tips.
Immunoprecipitation of FMRP-Containing mRNP Complex
1. Adult WT and Fmr1 congenic C57Bl/6J litter mates should be CO 2 -asphyxiated for 2 min (19) . Harvest whole brains and homogenize by 10-stroke dounce homogenization in 2 mL per brain ice-cold lysis buffer. For human cell lines, resuspend the cell pellets with lysis buffer. Perform all further manipulations of the lysates at 4°C or on ice. 2. Nuclei and debris are pelleted at 3000g for 10 min. The pellet is then washed with 1 mL lysis buffer, and pelleted again. The supernatants from both spins are pooled, raised to 300 mM NaCl, and clarified at 70,000g for 30 min. 3. Preclear the resulting supernatant for 1 h with 60 mL recombinant protein G agarose (washed with lysis buffer first). Pellet the preclearing matrix; the supernatant will be used as the precleared input (INPUT). Aliquots of INPUT should be saved for RNA extraction (200 mL) and pro-tein analysis (100 mL). 4. Add RNase inhibitor to the remaining lysates. Immunoprecipitate the lysates with approx 15 mg of monoclonal antibody conjugated to 60 mL of protein G agarose (see Note 1). 5. Lysates are immunoprecipitated for 2 h and washed three times for 10 min each with 1.5 mL lysis buffer. 
Determination of the Association Between FMRP and Small RNAs In Vivo
To determine the association between FMRP and small RNAs in vivo, the RNA samples are labeled at the 3'-termini with 5'-[ 32 P]pCp and separated by gel electrophoresis. Load the samples on a 15% TBE urea Bio-Rad Criterion precast gel and perform electrophoresis at 30 to 45 mA (0.5 h). 6. Stop the electrophoresis when the bromophenol blue dye has migrated to the bottom of the gel. 7. Dry the gel on a gel dryer and expose to X-ray film or a phosphorimager screen, according to the manufacturer's instructions (Fig. 2) .
Determination of the Interaction Between FMRP and Specific miRNAs Using Northern Blot Analysis (see Note 4)
Separation of RNAs on Polyacrylamide Gel
Transferring RNA to Membrane
Electroblotting can be performed in a semidry apparatus using a stack of three sheets of blotting paper soaked in 0.25X TBE, placed above and below the gel/membrane. antibodies using a human lymphoblastoid cell line from a normal individual. As a negative control, immunoprecipitation was also performed on a fragile X cell line, using an anti-FMRP antibody (Lane 2). The immunoprecipitated RNAs were isolated, 3'-end labeled with [5'-32 P]-pCp, and resolved by electrophoresis on 15% denaturing polyacrylamide gels. The bands for microRNAs and their precursors are indicated. The 32 P-label RNA size marker (Ambion) for 10 to 100 nucleotides was run in parallel on the left.
2. Finally, UV crosslink the RNA to the membranes using a UV crosslinker (120 mJ burst during 30 s).
Probe Preparation
DOUBLE-STRANDED DNA TRANSCRIPTION TEMPLATE PREPARATION
1. Resuspend the oligonucleotide template to 100 mM (100 pmol/mL). 2. Hybridize the oligonucleotide template to the T7 Promoter Primer. a. In a microcentrifuge tube mix the following: Amount Component 2 mL T7 promoter primer 6 mL DNA hybridization buffer 2 mL oligonucleotide template (100 mM) b. Heat the mixture to 70°C for 5 min, and leave at room temperature for 5 min to allow hybridization. 3. Fill in with Klenow DNA polymerase.
a. Add the following to the hybridized oligonucleotides: Amount Component 2 mL 10X Klenow reaction buffer 2 mL 10X deoxyribonucleoside triphosphate mix 4 mL Nuclease-free water 2 mL Exo-Klenow b. Incubate for 30 min at 37°C.
IN VITRO TRANSCRIPTION
1. Assemble the transcription reactions at room temperature and incubate for 10 to 30 min at 37°C. Amount Component Up to 20 mL nuclease-free water 1 mL double-stranded DNA template 2 mL 10X transcription buffer 1 mL 10 mM ATP 1 mL 10 mM cytidine triphosphate 1 mL 10 mM guanosine triphosphate 5 mL a-32 P-uridine triphosphate 2 mL T7 RNA Polymerase 2. Add 1 mL deoxyribonuclease I to the transcription reaction and incubate for 10 min at 37°C to remove the template DNA.
Prehybridization
Prehybridize the membrane in 10 mL of prehybridization solution for at least 1 h at 65°C. After prehybridizing, remove and discard the prehybridization solution.
Hybridization
Add 10 mL of hybridization solution. Hybridize the blot in approx 10 mL of Northern blot hybridization solution containing at least 4 ´ 10 5 cpm of 5' end-labeled antisense probe(s) for 8 to 24 h, with gentle agitation, at room temperature.
Wash and Expose
After hybridization, remove the hybridization solutions. 5. After the final wash, wrap the blots in plastic wrap and expose to X-ray film or a phosphorimager screen, according to the manufacturer's instructions (Fig. 3) . The latter method allows quantification of the amount of signal present in each band (1 h).
Notes
1. Immunoprecipitation. During the immunoprecipitation process, it is critical to control the RNase activity using extra RNase inhibitors. Reducing the time of immunoprecipitation could also effectively prevent RNA degradation. Therefore, immunoprecipitation overnight is not recommended and, in general, 1 to 2 h should be enough. In addition, it is important to include a negative control during the immunoprecipitation. In our case, the negative control is Fmr1 KO mouse. It is likely that antibody used in immunoprecipitation might also nonspecifically interact with some RNAs. Indeed, some RNAs could also be immunoprecipitated even from Fmr1 KO mice ( Figs. 1 and 2 ). 2. Microarray analysis. Different platforms of microarray could also be used in a similar assay.
Before target preparation, RNAs should be purified through RNeasy column (Qiagen). Otherwise, the labeling efficiency will be interfered with. In addition, the fold of enrichment used to determine the mRNAs that specifically interact with FMRP is arbitrary at this stage. Ideally, one or two known mRNA ligands could be used as internal controls to determine how many folds of enrichment should be used. 3. Labeling small RNAs. The RNAs used here should be isolated with Trizol or other RNA isolation reagents that would not remove small RNAs. The RNeasy column, which is required for microarray analysis, should not be used here because it will remove most small RNAs. 4. Northern blot. To prepare the template for in vitro transcription, an oligonucleotide containing specific miRNA sequences along with an 8-base sequence complementary to the 3' end of T7 promoter primer should be designed and synthesized. Because, in general, miRNAs are AU-rich, the hybridization and washing should be less stringent than when probing mRNA. In addition, some miRNAs are almost identical to each other, with only a one-or two-nucleotide difference. In this case, it will be very difficult to distinguish those miRNAs by Northern blot. Alternatively, one could design a probe specifically for each miRNA to perform the RNase protection assay (21).
